首页> 外文期刊>European Journal of Pharmacology: An International Journal >PKC and MAPK signalling pathways regulate vascular endothelin receptor expression.
【24h】

PKC and MAPK signalling pathways regulate vascular endothelin receptor expression.

机译:PKC和MAPK信号通路调节血管内皮素受体的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

Up-regulation of vascular endothelin type A (ET(A)) and type B (ET(B)) receptors are implicated in the pathogenesis of cardiovascular disease. Culture of arteries has been shown to induce similar receptor alterations and has therefore been suggested as a suitable method for in detail delineation of the regulation of endothelin receptors. We hypothesize that protein kinase C (PKC) and mitogen-activated kinases (MAPK) are involved in the regulation of endothelin receptors. Porcine coronary arteries were studied before and after 24 h of culture, using in vitro pharmacology, real-time PCR and immunofluorescence techniques. Sarafotoxin 6c and endothelin ET-1 were used to examine the endothelin ET(A) and ET(B) receptor effects. The involvement of PKC and MAPK in the receptor regulation was examined by culture in the presence of antagonists. Organ culture resulted in increased sarafotoxin 6c and endothelin-1 contractions, endothelin ET(A) and ET(B) receptor immunofluorescence staining intensities and endothelin ET(B), but not ET(A), receptor mRNA levels. The general PKC inhibitors, bisindolylmaleimide I (10 microM) or Ro-32-0432 (10 microM), inhibited these effects. Also, the increase in sarafotoxin 6c contraction, endothelin ET(B) receptor and mRNA levels and endothelin ET(A) and ET(B) immunofluorescence staining intensities were inhibited by MAPK inhibitors for extracellular signal related kinases 1 and 2 (ERK1/2), PD98059 (10 microM), C-jun terminal kinase (JNK), SP600125 (10 microM), but not by p38 MAPK, SB203580 (10 microM). In conclusion, PKC and MAPK seem to be involved in the regulation of endothelin receptor expression in porcine coronary arteries. Inhibiting these intracellular signal transduction pathways may provide a future therapeutic target for hindering the development of vascular endothelin receptor changes in cardiovascular disease.
机译:血管内皮素A型(ET(A))和B型(ET(B))受体的上调与心血管疾病的发病机制有关。已显示动脉培养可诱导类似的受体改变,因此已被建议作为一种详细描述内皮素受体调节的合适方法。我们假设蛋白激酶C(PKC)和有​​丝分裂原激活的激酶(MAPK)参与内皮素受体的调节。使用体外药理学,实时PCR和免疫荧光技术,在培养24小时之前和之后研究了猪冠状动脉。使用Sarafotoxin 6c和内皮素ET-1来检查内皮素ET(A)和ET(B)受体的作用。通过在拮抗剂存在下的培养来检查PKC和MAPK参与受体调节。器官培养导致sarafotoxin 6c和内皮素1的收缩,内皮素ET(A)和ET(B)受体的免疫荧光染色强度和内皮素ET(B)增加,但ET(A)受体mRNA水平增加。一般的PKC抑制剂,双辛基马来酰亚胺I(10 microM)或Ro-32-0432(10 microM),抑制了这些作用。此外,MAPK抑制剂对细胞外信号相关激酶1和2(ERK1 / 2)抑制了sarafotoxin 6c收缩,内皮素ET(B)受体和mRNA水平以及内皮素ET(A)和ET(B)免疫荧光染色强度的增加。 ,PD98059(10 microM),C-jun末端激酶(JNK),SP600125(10 microM),但不包含p38 MAPK,SB203580(10 microM)。总之,PKC和MAPK似乎参与了猪冠状动脉内皮素受体表达的调节。抑制这些细胞内信号转导途径可能为阻碍心血管疾病中血管内皮素受体变化的发展提供未来的治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号